The global viscosupplementation market size is expected to reach USD 12.94 billion by 2032, exhibiting a CAGR of 10.6% over the forecast period, 2024 – 2032.
The Viscosupplementation Market refers to the industry involved in providing treatments that involve the injection of hyaluronic acid or other lubricating agents into joints to alleviate symptoms associated with osteoarthritis (OA) and other joint conditions. Viscosupplementation helps restore the lost or degraded hyaluronic acid in the synovial fluid of joints, which acts as a lubricant and shock absorber, promoting smoother joint movement and reducing pain.
Growth Drivers of the Viscosupplementation Market
- Growing Prevalence of Osteoarthritis
- Osteoarthritis is the most common joint disorder, affecting millions of people worldwide. As the global population ages and lifestyles evolve, the prevalence of osteoarthritis, particularly in the knee joint, has been rising, driving the demand for viscosupplementation therapies.
- Preference for Non-Surgical Treatments
- Many patients and healthcare professionals prefer viscosupplementation treatments over surgery, as they are less invasive, carry fewer risks, and offer faster recovery times. The non-surgical nature of viscosupplementation has contributed to its growing adoption.
- Rising Aging Population
- As the global population ages, there is a higher incidence of age-related joint degeneration. Older individuals are more prone to conditions like osteoarthritis, which drives the need for viscosupplementation to manage joint pain and improve mobility.
Some of the major players operating in the global market include:
- Anika Therapeutics, Inc.
- DePuy Synthes
- F.Hoffmann-La Roche Ltd.
- Ferring Pharmaceuticals B.V.
- Fidia Farmaceutici S.p.A
- LG Life Sciences Ltd.
- Lifecore Biomedical
- Sanofi
- Seikagaku Corp.
Download Free Sample PDF Copy of the Report:
https://www.polarismarketresearch.com/industry-analysis/viscosupplement-market/request-for-sample
Key Trends in the Viscosupplementation Market
- Development of Longer-Lasting Formulations
- There is a strong trend toward developing longer-lasting viscosupplementation products that can offer relief for up to six months or more. These extended-release formulations improve patient compliance and reduce the need for frequent injections.
- Combination Therapies
- Increasingly, viscosupplementation is being used in combination with other treatments, such as corticosteroids or physical therapy, to optimize patient outcomes. Combining therapies helps address a broader range of symptoms and improves overall joint function.
- Minimally Invasive Treatments
- As patient preferences shift toward minimally invasive treatments, viscosupplementation has become a popular alternative to more invasive procedures like joint replacement. The increasing use of imaging technologies like ultrasound or fluoroscopy to guide injections has further enhanced the precision and effectiveness of these treatments.
Recent Developments
- In November 2022, Anika Therapeutics, Inc., a prominent joint preservation company, has effectively met the primary endpoint in the Phase III Study for Cingal. This medication is formulated to offer prolonged pain relief for individuals dealing with knee osteoarthritis (OA). The company is focused on securing FDA clearance for Cingal and its introduction to the United States. Successful trials of this nature empower companies to enhance their research and development endeavors, providing them with a competitive edge in the market.
- In April 2022, Juniper Biologics and Kolon Life Sciences have entered into a licensing arrangement to develop and commercialize TissueGene-C low dose (TG-C LD), an investigational therapy tailored for non-surgical treatment through a single intra-articular injection, specifically addressing knee osteoarthritis. As per the terms of the licensing agreement, Juniper will lead the efforts in developing and promoting this gene therapy, with a focus on medical professionals and hospitals in the Asia-Pacific, Middle East, and Africa regions.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:
The research study includes segmental analysis that divides the market into distinct groups or segments based on common characteristics. With market segmentation, businesses can identify specific customer groups that are more likely to be interested in specific products or services. Also, it enables these businesses to focus their marketing efforts and resources more efficiently, leading to higher conversion rates and improved return on investment. Furthermore, segmentation analysis helps companies develop personalized products or services, which can result in increased customer loyalty and improved customer satisfaction.
Viscosupplementation, Product Outlook (Revenue – USD Billion, 2019 – 2032)
- Three Injection
- Five Injection
- Single Injection
Viscosupplementation, End-Use Outlook (Revenue – USD Billion, 2019 – 2032)
- Orthopedic Clinics/ASCs
- Hospitals
The viscosupplementation market is experiencing significant growth, driven by the rising prevalence of osteoarthritis, advancements in hyaluronic acid formulations, and the growing preference for non-invasive treatments. As the market continues to expand, it presents ample opportunities for companies to innovate and address the needs of patients seeking effective, less invasive solutions for joint pain.